Intercurrent Illness and Care After the Trial
Part of Principal Investigator (PI) Training: Medical Care of the Participant.
About 4 minutes. Free, in your language, no account needed.
Why this matters
Section 2.7.1(c) contains two obligations that sites routinely under-read. The first is that adequate medical care for trial-related adverse events, including clinically significant laboratory values, continues following participation — not only during it. The second is that the participant should be informed when medical care is needed for intercurrent illness, meaning conditions that arise alongside the trial and are not caused by it.
Both are about the period when everyone's attention has moved on. That is precisely why they are written down.
Intercurrent illness
A participant develops something unrelated to the trial: an infection, an injury, a new diagnosis. Three things follow.
Tell them. The obligation is explicit — where medical care is needed, the participant is informed. This sounds obvious until you consider how findings actually surface: in a batch of safety laboratory results reviewed by a coordinator, in a report from a central laboratory, in an imaging study read by someone who is not treating them. Findings can be recorded correctly and never reach the person.
Close that gap with a rule: every clinically significant result is reviewed by an investigator within a defined time, and any result requiring action generates a documented contact with the participant.
Decide whether it affects the trial. Does the illness make continuation unsafe? Does its treatment introduce a prohibited medication? Does it confound the endpoint? These are your decisions, not the coordinator's, and they should be recorded as decisions with reasons.
Record it correctly. An intercurrent illness is usually still an adverse event for reporting purposes — an untoward medical occurrence in a participant — even where you assess it as unrelated. Not related is a causality assessment, not a reason to omit the event. Module 7 covers this distinction.
Care that continues after participation
The obligation in §2.7.1(c) extends beyond the participant's last visit for trial-related events. In practice:
- A participant who leaves with an ongoing trial-related event is followed until it resolves, stabilizes, or is otherwise explained — not until the database closes.
- A participant withdrawn early is not thereby discharged from care for anything the trial caused.
- An event that emerges after the last visit but is plausibly trial-related still needs assessment, and often still needs reporting.
Say this at consent, in your own words. Participants frequently assume the relationship ends with the final visit, and the assumption is not unreasonable given how trials are described to them.
Post-trial access to treatment
A separate and harder question: what happens to a participant who benefited from an investigational product once the trial ends?
E6(R3) does not create an access entitlement. The Declaration of Helsinki addresses post-trial provisions and expects them to be considered and described in advance. Many protocols include an extension study, a compassionate-use route or a managed-access program; many do not.
The obligation you can meet regardless is honesty about it, at the right time. Find out at start-up what happens at the end. Tell participants during consent, accurately, including "nothing is currently planned" if that is the truth. Raise it again with the sponsor before the trial closes if a participant is clearly benefiting. Then document the answer.
What causes real distress is not the absence of post-trial access. It is discovering its absence in the final week, from a coordinator, having assumed otherwise for two years.
Key takeaways
- §2.7.1(c) has two limbs: adequate care for trial-related events during and following participation, and informing the participant when care is needed for intercurrent illness.
- Build a rule that every clinically significant result reaches an investigator and, where action is needed, generates a documented contact with the participant.
- An intercurrent illness assessed as unrelated is still normally a reportable adverse event.
- Post-trial access is not created by E6(R3); find out the position at start-up and tell participants the truth early.